1. Z, Wang. S, Wang. J, Qin. X, Zhang. G, Lu. H, Liu. H, Guo. L, Wu. V, Shender. C, Shao. B, Kong. Z, Liu. Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12,Nature Communications,202210.1038/s41467-022-34042-w
2. Qin J, Huang T, Wang Z, Zhang X, Wang J, Dang Q, Cui D, Wang X, Zhai Y, Zhao L, Lu G, Shao C, Li S, Liu H, Liu Z. Bud31-mediated alternative splicing is required for spermatogonial stem cell self-renewal and differentiation,Cell Death Differ,2022. 10.1038/s41418-022-01057-1
3. Y. Wang, X. Zhang, W. Tang, Z. Lin, L. Xu, R. Dong, Y. Li, J. Li, Z. Zhang, X. Li, L. Zhao, J.J. Wei, C. Shao, B. Kong,Z. Liu, miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-kappaB in high-grade serous ovarian carcinoma,Cell Death Differ,24 (2017) 2089-2100.
4. Wang S, Wang Z, Li J, Qin J, Song J, Li Y, Zhao L, Zhang X, Guo H, Shao C, Kong B, Liu Z. Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2.Cell Death Dis2021, 12(4): 294.
5. X. Tian, J. Song, X. Zhang, M. Yan, S. Wang, Y. Wang, L. Xu, L. Zhao, J.J. Wei, C. Shao, B. Kong,Z. Liu, MYC-regulated pseudogene HMGA1P6 promotes ovarian cancer malignancy via augmenting the oncogenic HMGA1/2,Cell Death Dis, 11 (2020) 167.